Please login to the form below

Not currently logged in
Email:
Password:

Wyeth makes new hires

Wyeth makes two new appointments to its Women's Health Care Business Unit

The pharmaceutical division of Wyeth has appointed Cathy Kerzner to the position of senior vice-president and general manager of the company's Women's Health Care Business Unit.

Kerzner will lead the commercial aspects of Wyeth's portfolio of the unit's products on a global basis and will report to Joseph Mahady, president of global businesses of Wyeth Pharmaceuticals.

She had spent 14 years with Wyeth in a number of commercial capacities before advancing to the position of vice-president of business strategy and then vice-president of commercial strategy for Cardinal Health. Kerzner founded EKR Therapeutics, a US-based start-up specialty pharmaceutical company.

In addition, Wyeth has promoted Dr Michael Dey to the position of president of scientific affairs for women's health. Dey will focus on efforts to advance the understanding of the science that supports both new and existing female healthcare products at the firm. He will also report to Mahady.

Dey joined Wyeth-Ayerst R&D in 1984 and headed Wyeth's generic pharmaceutical business for eight years. Since 2001, he has served as president and general manager of the Women's Health Care arm.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics